Attenuating the opioid epidemic may involve the use of new genetic tools, especially in pain clinics, to determine an individuals’ predisposition for addiction risk for opiates. The session will present data on the Genetic Addiction Risk Score (GARS), a 10-reward gene panel that has shown that the presence of risk alleles can significantly predict ASI-Alcohol and Drug severity. New information includes GARS testing in patients volunteering for spinal cord pain surgery to determine genetic risk for opioid addiction, a project demonstrating the use of GARS to determine relapse risk and appropriate allocation of resources to a minority community. Two other studies that will be presented are a validation study of a Reward Deficiency Syndrome questionnaire and a pharmacokinetic study involving the p450 system to determine the metabolic rate of patients on buprenorphine/naloxone. Presenters will discuss the effect of increasing the dose of buprenorphine/naloxone on subsequent illicit opiate abuse. Based on this research, they will propose a model for treatment of Reward Deficiency Syndrome.
Upon completion of this session, attendees will be able to:
Describe the 10 gene panel for the GARS test.
Summarize the list of clinical benefits for the utilization of GARS.
Explain how the p450 genotyping will help in dosing buprenorphine.